NCT05868265 - A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 2, 2023

Primary Completion Date

June 2, 2026

Study Completion Date

June 2, 2026

Conditions

Urothelial Carcinoma

Interventions

DRUG

Enfortumab Vedotin

All patients will receive enfortumab vedotin at 1.25 mg/kg on days 1 and 8 of 21 days cycle, for a total of three cycles.

PROCEDURE

Radical surgery

Radical surgery, such as radical nephroureterectomy, nephrectomy or ureterectomy is to take place within 60 days from the last dose of treatment end of cycle 3 (i.e., cycle 3 day 22).

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited protocol activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors

collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER